FDA Drug Recalls

Recalls / Class II

Class IID-0382-2023

Product

Daptomycin for Injection 500 mg per vial, Single-dose vial, Rx only, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. NDC 16729-435-05 UPC 3 16729 43505 5.

Brand name
Daptomycin
Generic name
Daptomycin
Active ingredient
Daptomycin
Route
Intravenous
NDC
16729-435
FDA application
ANDA211961
Affected lot / code info
Batches: R2101282, Exp. Date 9/30/2023; R2101600,Exp. Date 11/30/2024; R2200002, R2200028, R2200116, R2200142, R2200152, Exp. Date 12/31/2024; R2200165, R2200190, Exp. Date 1/31/2025; R2201042, Exp. Date 7/31/2025;

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Recalling firm

Firm
Accord Healthcare, Inc.
Manufacturer
Accord Healthcare Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1009 Slater Rd Ste 210B, N/A, Durham, North Carolina 27703-8446

Distribution

Quantity
228,760 vials
Distribution pattern
United States including Puerto Rico and Canada

Timeline

Recall initiated
2023-02-07
FDA classified
2023-03-02
Posted by FDA
2023-03-08
Terminated
2024-04-22
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0382-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.